Trial · NCT01119118
ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate Cancer
NCT01119118, Phase 2, Terminated, University of Wisconsin, Madison; results first posted 2013-04-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate Cancer. Trials, record NCT01119118. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01119118
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate Cancer
- NCT number
- NCT01119118
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 6 participants, actual
- Lead sponsor
- University of Wisconsin, Madison
- Conditions
- Prostate Cancer
- Interventions
- ZD4054
- First posted
- 2010-05-07
- Last updated
- 2019-11-21
- Results first posted
- 2013-04-29
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Number of Subjects Whose Tumor Lesion Size Changed After 6 Weeks of Treatment With ZD4054 Using PET and MRI Scans. | Week 6 | Multimodal Positron Emission Tomography (PET) and Magnetic Resonant Imaging (MRI) imaging were used to evaluate changes in the tumor lesion size following 6 weeks of treatment with ZD4054. |
| Secondary | The Number of Subjects Whose Tumor Lesion Size Changed Using Positron Emission Tomography (PET) Imaging Alone. | Week 6 | |
| Secondary | The Number of Subjects Whose Tumor Lesion Size Changed Using Diffusion-weighted Imaging (DWI)-Magnetic Resonant Imaging (MRI) Alone | Week 6 | |
| Secondary | Number of Subjects Whose Tumor Lesion Size Changed Using Iterative Decomposition of Water and Fat With Echo Asymmetry and Least-squares Estimation (IDEAL)-MRI Imaging Alone | Week 6 | |
| Secondary | Number of Subjects With PSA Response | 6 months |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Number of Subjects Whose Tumor Lesion Size Changed After 6 Weeks of Treatment With ZD4054 Using PET and MRI Scans. | Week 6 | participants | NUMBER | |
| SECONDARY | The Number of Subjects Whose Tumor Lesion Size Changed Using Positron Emission Tomography (PET) Imaging Alone. | Week 6 | participants | NUMBER | |
| SECONDARY | The Number of Subjects Whose Tumor Lesion Size Changed Using Diffusion-weighted Imaging (DWI)-Magnetic Resonant Imaging (MRI) Alone | Week 6 | participants | NUMBER | |
| SECONDARY | Number of Subjects Whose Tumor Lesion Size Changed Using Iterative Decomposition of Water and Fat With Echo Asymmetry and Least-squares Estimation (IDEAL)-MRI Imaging Alone | Week 6 | participants | NUMBER | |
| SECONDARY | Number of Subjects With PSA Response | 6 months | participants | NUMBER |
Source ClinicalTrials.gov
Results by group5
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Number of Subjects Whose Tumor Lesion Size Changed After 6 Weeks of Treatment With ZD4054 Using PET and MRI Scans. | ZD4054 | 0 | participants | ||
| The Number of Subjects Whose Tumor Lesion Size Changed Using Positron Emission Tomography (PET) Imaging Alone. | ZD4054 | 0 | participants | ||
| The Number of Subjects Whose Tumor Lesion Size Changed Using Diffusion-weighted Imaging (DWI)-Magnetic Resonant Imaging (MRI) Alone | ZD4054 | 0 | participants | ||
| Number of Subjects Whose Tumor Lesion Size Changed Using Iterative Decomposition of Water and Fat With Echo Asymmetry and Least-squares Estimation (IDEAL)-MRI Imaging Alone | ZD4054 | 0 | participants | ||
| Number of Subjects With PSA Response | ZD4054 | 0 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | ZD4054 | 6 | |
| Overall Study | COMPLETED | ZD4054 | 5 | |
| Overall Study | NOT COMPLETED | ZD4054 | 1 |
Source ClinicalTrials.gov
Adverse events45
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip) | Respiratory, thoracic and mediastinal disorders | ZD4054 | 2 | 6 | 2 |
| other | Lymphopenia | Blood and lymphatic system disorders | ZD4054 | 1 | 6 | 1 |
| other | Cardiac Arrhythmia | Cardiac disorders | ZD4054 | 2 | 6 | 2 |
| other | Fatigue (asthenia, lethargy, malaise) | General disorders | ZD4054 | 2 | 6 | 2 |
| other | Fever | General disorders | ZD4054 | 3 | 6 | 3 |
| other | Insomnia | Psychiatric disorders | ZD4054 | 1 | 6 | 1 |
| other | Weight loss | Investigations | ZD4054 | 1 | 6 | 1 |
| other | Anorexia | Metabolism and nutrition disorders | ZD4054 | 3 | 6 | 3 |
| other | Diarrhea | Gastrointestinal disorders | ZD4054 | 3 | 6 | 3 |
| other | Distension/bloating, abdominal | Gastrointestinal disorders | ZD4054 | 2 | 6 | 2 |
1 to 10 of 45Source ClinicalTrials.gov
See all 45 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | ZD4054 | ||
| Total, other adverse events | ZD4054 | 6 | 6 |
| Total, serious adverse events | ZD4054 | 4 | 6 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 25128349 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01119118
GET https://conductscience.org/api/trials/v1/NCT01119118/events?page=2